Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, randomized, observer-blinded, single centre trial evaluating the immunogenicity and safety of 2 doses of an adjuvated TB subunit vaccine (Ag85B-ESAT-6 + IC31®) using 2 different vaccination schedules in healthy adolescents

Trial Profile

A phase II, randomized, observer-blinded, single centre trial evaluating the immunogenicity and safety of 2 doses of an adjuvated TB subunit vaccine (Ag85B-ESAT-6 + IC31®) using 2 different vaccination schedules in healthy adolescents

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs H1IC (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms THYB-04
  • Sponsors Statens Serum Institut

Most Recent Events

  • 31 Mar 2014 Planned initiation date changed to 27 Aug 2012 according to Pan African Clinical Trials Registry record.
  • 31 Mar 2014 Status changed from recruiting to completed according to Pan African Clinical Trials Registry record.
  • 31 Mar 2014 New source identified and integrated (Pan-African Clinical Trials Registry).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top